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http://www.biomedcentral.com/1471-2474/14/44RESEARCH ARTICLE Open AccessExtracorporeal shockwave therapy shows a
number of treatment related chondroprotective
effect in osteoarthritis of the knee in rats
Ching-Jen Wang1*, Shan-Ling Hsu1, Lin-Hsiu Weng1, Yi-Chih Sun2 and Feng-Sheng Wang2Abstract
Background: Extracorporeal shockwave therapy (ESWT) shows chondroprotective effect in osteoarthritis of the rat
knees. However, the ideal number of ESWT is unknown. This study investigated the effects of different numbers of
ESWT in osteoarthritis of the knee in rats.
Methods: Forty-five male Sprague–Dawley rats were divided into five groups. Group I underwent sham arthrotomy
without anterior cruciate ligament transection (ACLT) or medial meniscectomy (MM) and received no ESWT. Group
II underwent ACLT + MM and received no ESWT. Group III underwent ACLT +MM, and received ESWT once a week
for one treatment. Group IV underwent ACLT + MM and received ESWT twice a week for 2 treatments. Group V
underwent ACLT + MM and received ESWT three times a week for 3 treatments. Each treatment consisted of 800
impulses of shockwave at 14 Kv to the medial tibia condyle. The evaluations included radiographs of the knee,
histomorphological examination and immunohistochemical analysis at 12 weeks.
Results: At 12 weeks, group II and V showed more radiographic arthritis than groups I, III and IV. On
histomorphological examination, the Safranin O matrix staining in groups III and IV are significantly better than in
groups II and V, and the Mankin scores in groups III and IV are less than groups II and V. Groups III and IV showed
significant decreases of Mankin score and increase of Safranin O stain as compared to group I. Group V showed
significant increases of Mankin score and a decrease of Safranin O stain as compared to group II. In articular cartilage,
group II showed significant increase of MMP13 and decrease of collagen II as compared to group I. Groups III and IV
showed significant decrease of MMP13 and increase of collagen II as compared to group I. Group V showed significant
increase of MMP13 and decrease of collagen II as compared to group II. In subchondral bone, vWF, VEGF, BMP-2 and
osteocalcin significantly decreased in groups II and V, but increased in groups III and IV relative to group I.
Conclusions: ESWT shows a number of treatment related chondroproctective effect in osteoarthritis of the knee in rats.
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Osteoarthritis (OA) of the knee has long being considered
primarily a cartilage disease associated with cartilage loss
and degradation. However, OA is usually accompanied by
changes in the subchondral and periarticular bone such as
sclerosis, bone cyst and osteophyte formation [1,2]. The
relationship between the subchondral bone changes and
the initiation and progression of OA is still debated [3-5].* Correspondence: W281211@adm.cgmh.org.tw
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reproduction in any medium, provided the orEmerging evidence shows that bone turnover increases in
patients with osteoarthritis with subchondral bone loss in
the early stage of OA and bone formation with osteo-
phytes in the late stage [6-9]. Some authors proposed the
potential role of subchondral bone changes in the initi-
ation and progression of OA [10,11]. It was suggested that
increased subchondral bone stiffness reduces the ability of
knee joint to dissipate the load and distribute the forces
within the joint, and increases the force load on the over-
lying articular cartilage, which in turn accelerates the
cartilage damage over time [6,9]. Therefore, the functio-
nal integrity of the articular cartilage depends on thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A knee sketch shows the location of shockwave
application in A-P (1-A) and lateral view (1-B).
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osteoarthritis of the knee, the initial focus of treatment
on articular cartilage or in subchondral bone remains
controversial.
Extracorporeal shockwave therapy (ESWT) has shown
effectiveness in many orthopedic disorders including soft
tissue tendinopathy and non-union of long bone frac-
tures [12,13]. In addition, many studies reported positive
effects of ESWT in various arthritic joints in animals
[14-18]. Other studies demonstrated that ESWT is chon-
droprotective in the initiation of OA changes of the knee
[19], and induces regression or retardation of established
OA changes of the knee in rats [20]. The ESWT dosages
in the studies were based on the results of a pilot studyFigure 2 Radiographs of the knee at 12 weeks show more advanced
changes in groups I, III and IV.that demonstrated 800 impulses of shockwave at 14 Kv
applied to the subchondral bone of the medial tibia con-
dyle showed better effects than 200, 400 and 1200
impulses in small animals. However, the optimal dosage
and the ideal number of ESWT in osteoarthritis of the
knee are unknown. Furthermore, many studies reported
a dose-related effect of ESWT in bone [21], tendon [22],
epigastric skin flap [23], tenocyte [24], and cells [25]. We
hypothesized that the effect of ESWT in osteoarthritis of
the knee may be related to the number of ESWT treat-
ment. The purpose of this study was to investigate the
effect of different numbers of ESWT treatment in osteo-
arthritis of the knee in rats.
Methods
The Institutional Review Board on animal experiment of
Chang Gung Memorial Hospital, Taiwan approved this
study. All studies were performed in accordance with
the guidelines in the study and the care of animals in
experiment.
Study design
This study was performed in 45 male Sprague–Dawley
rats of 10-week old with body weight ranging from 275 mg
to 315 mg. The anterior cruciate ligament transected
(ACLT) and medial meniscectomized (MM) osteoarthritis
knee model in rat was used [8]. The animals were divided
into five groups with 9 rats in each group. Group I was
the control and underwent sham arthrotomy of the knee
without ACLT or MM and received no ESWT. Group II
underwent ACLT and MM but no ESWT. Group III
underwent ACLT +MM and received ESWT once a week
for one treatment. Group IV underwent ACLT and MM
and received ESWT twice a week for two treatments.
Group V underwent ACLT and MM and received ESWT
three times a week for three treatments. Radiographs of
the knee in anteroposterior and lateral projections were
performed at 0 and 12 weeks. Radiographs of the knee
were obtained to assess bony appearance, focal osteo-osteoarthritis of the knee in groups II and V, and less arthritic
Table 1 The results of Mankin score and Safranin O stain
Mankin score
Group I Group II Group III Group IV Group V
1 (1–1) 10 (9–12) 1 (0–2) 3 (2–4) 10 (8–11)
P1 = 0.0088 P2 = 1 P3 = 0.0742 P4 = 0.0102
P5 = 0.0017 P6 = 0.0038 P7 = 0.6213
P8 = 0.0705 P9 = 0.0022
P10 = 0.0052
Safranin O
Group I Group II Group III Group IV Group V
1 (1–1) 18.7 (16–20) 0.7 (0–1) 1.3 (1–2) 15 (12–17)
P1 = 0.0056 P2 = 0.4226 P3 = 0.4226 P4 = 0.0117
P5 = 0.0036 P6 = 0.0039 P7 = 0.1461
P8 = 0.2302 P9 = 0.0087
P10 = 0.0096
Group I: the control; Group II: ACLT +MM; Group III: ACLT +MM+ ESWT 1×/week;
Group IV: ACLT +MM+ ESWT 2×/week; Group V: ACLT +MM+ ESWT 3×/week.
ACLT: anterior cruciate ligament transection; MM: medial meniscectomy; ESWT:
extracorporeal corporeal shockwave therapy.
P1: Group I vs Group II P2: Group I vs Group III P3: Group I vs Group IV.
P4: Group I vs Group V P5: Group II vs Group III P6: Group II vs Group IV.
P7: Group II vs Group V P8: Group III vs Group IV P9: Group III vs Group V.
P10: Group IV vs Group V.
The P values were obtained using ANOVA and post hoc test with Bonferoni
correction among five groups, and the Mann–Whitney U test between
two groups.
Figure 3 The results of Mankin score and Safranin O stain.
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animals were sacrificed at 12 weeks and the knee speci-
mens were subjected to histomorphological examination
and immunohistochemical analysis.
Anterior cruciate ligament transection and medial
meniscectomy
The animals were sedated with intra-peritoneal pheno-
barbital injection (50 mg/Kg body weight). The left knee
was prepared and draped in surgically sterile fashion. A
straight anterior skin incision was made and the knee joint
was opened through medial parapatellar arthrotomy. The
anterior cruciate ligament was transected with a scalpel.
Medial meniscectomy was performed by excising the en-
tire medial meniscus. The knee was irrigated and the
wound was closed in routine fashion. The animals were
returned to the housing cages and were under the care of
the veterinarian.
Shockwave application
ESWT was administered in groups III, IV and V in one
week after knee surgery when the wound healed. The
animals were sedated with intra-peritoneal phenobarbital
injection (50 mg/Kg body weight). The source of shock-
wave is from an OssaTron orthotriptor (Sanuwave,
Alpharetta, GA). The focus of shockwave treatment wasthe subchondral bone of the medial tibia condyle that
was approximately 0.5 cm below the medial tibia plateau
in anteroposterior view and 0.5 cm from the medial skin
in lateral view (Figure 1). The depth of treatment was
confirmed with the laser indicator of the shockwave
device. Ultrasound gel was applied to the skin in contact
with the shockwave tube. Each treatment consisted of
the application of 800 impulses of shockwave at 14 Kv
(equivalent to 0.22 mJ/mm2). ESWT was performed
once in group III, twice in group IV and three times in
group V. After ESWT, the animals were returned to the
housing cages and are under the care of the veterinarian.
Histomorphological examination
The animals were sacrificed at 12 weeks. The knee spe-
cimens including the articular cartilage and the sub-
chondral bone of proximal tibia and distal femur were
harvested. The specimens were decalcified and fixed in
paraffin, and cut into 5-um thick sections using micro-
derme and stained with heamtoxylin-eosin, Safranin-O,
thionine and Alcian blue stains. The microscopic fea-
tures of the articular cartilage included fissuring of the
cartilage, chondrocyte proliferation, chondrocyte activity
and chondrocyte apoptosis. The cartilage degradation
was assessed by Mankin score that included cartilage
structure, cartilage cells and tidemark integrity [26]. The
matrix content was measured with Safranin O staining.
The subchondral bone remodeling was evaluated with
tissue distributions including cortical bone, cancellous
bone and fibrous tissue.
Immunohistochemical analysis
The specimens were fixed in 4% PBS-buffered parafor-
maldehyde for 48 hours and decalcified in PBS-buffered
10% EDTA. Decalcified tissues were embedded in paraf-
fin. The specimens were cut longitudinally into 5-um
thick sections and transferred to poly-lysine-coated
slides. Sections of the specimens were immunostained
with specific reagents for vWF (von Willebrand Factor),
VEGF (vessel endothelial growth factor), BMP-2 (bone
morphogenic protein 2) and osteocalcin in subchondral
Figure 4 Microscopic features of the articular cartilage and subchondral bone in histomorphological examination.
Table 2 The results of MMP13 and collagen II in articular
cartilage
MMP13 (%)









P1 = 0.0008 P2 = 0.3467 P3 = 0.1643 P4 < 0.0001
P5 = 0.0005 P6 = 0.0008 P7 = 0.1578
P8 = 0.1307 P9 < 0.0001
P10 = 0.0027
Collagen II (%)











P1 < 0.0001 P2 = 0.1142 P3 = 0.2007 P4 = 0.0001
P5 = 0.0002 P6 = 0.0001 P7 = 0.1319
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collagen II in articular cartilage (Santa Cruz Biotechnology
Inc, CA, USA). The immuno-reactivity in specimens was
demonstrated using a horseradish peroxidase (HRP)-30-,
30-diaminobenzidine (DAB) cell and tissue staining kit
(R & D Systems, Inc. Minneapolis, MN, USA). The
immuno-activities were quantified from five areas in three
sections of the same specimen using a Zeiss Axioskop 2
plus microscope (Carl Zeiss, Gottingen, Germany). All the
images of each specimen were captured using a Cool
CCD camera (SNAP-Pro c.f. Digital kit; Media Cybernet-
ics, Sliver Spring, MD, USA). Images were analyzed using
an Image-ProW Plus image-analysis software (Media Cy-
bernetics, Sliver Spring, MD, USA). The percentage of
positive immuno-labeled cells over the total cells in each
area was counted. A pathologist blinded to the nature of
the study performed the measurements on all sections.
The cartilage degradation was assessed with the mea-
surements of MMP-13 and collagen II in the articular car-
tilage, and the subchondral bone remodeling by the mea-
surements of vWF, VEGF, BMP-2 and osteocalcin.
Statistical analysis
The results of this study were expressed in median with
ranges. Group I data were used as the baseline for statis-
tical comparison with other groups. The P-values were
obtained using ANOVA and post hoc test with Bonferoni
correction among five groups, and Mann–Whitney “U”
test between two groups. A statistical significance was set
at p < 0.05.P8 = 0.6280 P9 = 0.0005
P10 = 0.0003
P1: Group I vs Group II P2: Group I vs Group III P3: Group I vs Group IV.
P4: Group I vs Group V P5: Group II vs Group III P6: Group II vs Group IV.
P7: Group II vs Group V P8: Group III vs Group IV P9: Group III vs Group V.
P10: Group IV vs Group V.
The P values were obtained using ANOVA and post hoc test with Bonferoni
correction among five groups, and the Mann–Whitney U test between
two groups.Results
Radiographs of the knee showed no discernable differ-
ence among the 5 groups at 0 week. However, at 12
weeks, groups II and V showed more radiographic arth-
ritis than groups I, III and IV (Figure 2).The results of Mankin score and Safranin O matrix
staining are summarized in Table 1 and Figure 3. The
microscopic features are shown in Figure 4. The Safranin
O matrix staining in group III and IV is significantly bet-
ter than in groups II and V, and the Mankin scores in
groups III and VI are less than groups II and V. The
figures reflect a decreased Safranin O staining and an
increased Mankin score associated with progression of
osteoarthritis of the knee. The knees that were treated
with one and two ESWT treatments showed significantly
Figure 5 The results of MMP13 and collagen II in
articular cartilage.
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treated with three ESWT treatments.
The results of MMP13 and collagen II of the articular
cartilage are summarized in Table 2 and Figure 5. The
microscopic features are shown in Figure 6. Group II
showed significant increase of MMP13 and decreases of
collagen II as compared to group I indicating the pro-
gression of the knee arthritis. The changes of MMP-13
and collagen II in groups III and IV were comparable to
group I, however, the changes in group V are closely
similar to group II.
The results of vWF, VEGF, BMP-2 and osteocalcin in
subchondral bone are summarized in Table 3 and
Figure 7. The microscopic features are shown in Figure 8.
Group II showed significant decreases of vWF, VEGF,
BMP-2 and osteocalcin as compared to group I. Group
III and IV showed significant increases of vWF, VEGF,
BMP-2 and osteocalcin with the data comparable to
group I. However, group V showed significant decreases
of vWF, VEGF, BMP-2 and osteocalcin comparable to
group II. It appears that one or two ESWT treatments
showed beneficial effects, however, three ESWT treat-
ments caused deteriorating changes.Figure 6 Microscopic features of MMP13 and collagen II in articular cDiscussion
The results of the current study showed that ESWT pro-
tects the articular cartilage degradation and improves
subchondral bone remodeling in the initiation of osteo-
arthritis of the knee in rats. The results are in agreement
with prior studies that shockwave has chondroprotective
effect in OA knee in rats [19,20], The subchondral bone
remodeling relies on the balance between bone forma-
tion by osteoblast and bone resorption by osteoclast,
and is influenced by the subchondral bone mass and
bone strength. The effects on articular cartilage were
supported by the changes of Mankin score, Safranin O
stain, MMP-13 and collagen II. MMP-13 is involved in
cartilage turnover and cartilage pathophysiology asso-
ciated with osteoarthritis. Collagen II is the base of ar-
ticular cartilage and hyaline cartilage that form fibrillar
network of collagen that allows cartilage to entrap the
proteoglycan aggregate and provide tensile strength to
the tissue. The effects of ESWT in subchondral bone
remodeling were supported by the increased vascu-
larization manifested by the changes of vWF, eNOS and
VEGF, and osteogenesis manifested by the changes in
BMP-2, alkaline phosphatase and osteocalcin. vWF is a
large glycoprotein in plasma and endothelium and a
positive vWF is indicative of new vessel formation.
eNOS is an immune transmitter and vasodilator in tissue
healing . VEGF is a protein that stimulates vasculogen-
esis and angiogenesis and an indication of increased vas-
cular permeability and microvascular activities including
the angiogenic growth of new vessels. BMP-2 is osteoin-
ductive and induces osteoblast differentiation. Alkaline
phosphatase is a hydrolase enzyme responsible for
dephosphorylation. Osteocalcin is pre-osteoblastic and
bone-building in nature.
The current study also demonstrated that ESWT has a
number of treatment related effect in osteoarthritis of
the knee. Many studies reported dose-dependent effects
of ESWT in different tissues [21-25]. ESWT showed aartilage in immunohistochemical stains.
Table 3 The results of vWF, VEGF, BMP-2 and osteocalcin
in subchondral bone
vWF (%)











P1 = 0.0001 P2 = 0.8696 P3 = 0.1253 P4 < 0.0001
P5 = 0.0012 P6 = 0.0044 P7 = 0.9899
P8 = 0.1156 P9 = 0.0004
P10 = 0.0022
VEGF (%)











P1 = 0.0001 P2 = 0.1239 P3 = 0.3432 P4 < 0.0001
P5 = 0.0003 P6 = 0.0001 P7 = 0.6777
P8 = 0.3540 P9 = 0.0005
P10 = 0.0001
BMP2 (%)











P1 = 0.0008 P2 = 0.4670 P3 = 0.0729 P4 = 0.0026
P5 = 0.0027 P6 < 0.0001 P7 = 0.5312
P8 = 0.2893 P9 = 0.0054
P10 = 0.0002
OCN (%)











P1 = 0.0029 P2 = 0.6008 P3 = 0.3741 P4 = 0.0016
P5 = 0.0025 P6 = 0.0045 P7 = 0.8010
P8 = 0.2002 P9 = 0.0014
P10 = 0.0029
P1: Group I vs Group II P2: Group I vs Group III P3: Group I vs Group IV.
P4: Group I vs Group V P5: Group II vs Group III P6: Group II vs Group IV.
P7: Group II vs Group V P8: Group III vs Group IV P9: Group III vs Group V.
P10: Group IV vs Group V.
The P values were obtained using ANOVA and post hoc test with Bonferoni
correction among five groups, and the Mann–Whitney U test between
two groups.
Figure 7 The results of vWF, VEGF, BMP-2 and osteocalcin in
subchondral bone.
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strength after fracture of the femur in rabbits [21]. Other
study reported a dose-related effect of shockwaves on
rabbit tendon Achilles [22]. In a murine skin flap model,
ESWT between 500 and 2500 impulses showed a dose-
dependent effect in epigastric flap survival [23]. ESWT
also showed dose-dependent changes in cell viability,
MMP 1, 2 and 3 and IL-6 on cultured tenocytes [24].
Another study stated that one of the most importantaspects to be considered is not the total number of
impulses used but the energy level of the shockwaves,
thus confirming that ESWT has a dose-dependent effect
on osteoblast cells [25]. An optimal ESWT dosage may
result in beneficial effects, whereas, overdose of ESWT
can cause deteriorating effect and damage to the
subchondral bone and articular cartilage of the knee.
The current study demonstrated that one or two ESWT
treatments showed beneficial effect, however, three
ESWT treatments caused deteriorating results. Add-
itional studies including clinical trial are needed to valid-
ate the ideal numbers of ESWT for osteoarthritis of the
knee in humans.
The exact mechanism of ESWT remains unknown.
Recent studies showed that ESWT induces the ingrowth
of neovascularization and up-regulation of angiogenic
and osteogenic growth factors that leads to improvement
in blood perfusion and tissue regeneration [27]. The
innovative findings in this study may unveil a new con-
cept in the management of osteoarthritis of the knee by
shifting the initial treatment focus from the articular
cartilage to the subchondral bone. Furthermore, ESWT
has the potential used in the treatment of osteoarthritis
of the knee.
There are limitations in this study. The data obtained
from this study were based on experiments in small
animals. The results may differ in larger animals or
human subjects. The dose conversion (energy level and
the total energy) from small animals to larger animals or
human subjects must be validated with additional stud-
ies including clinical trial. This study demonstrated that
the effect of ESWT is related to the number of treat-
ment, but not necessarily the dosage in knee OA, and
the optimal ESWT dosage and the ideal numbers of
ESWT treatment remains unknown. Furthermore, differ-
ent manufacture companies used different indices of
shockwave parameters, and the dose conversion formula
among the different devices are not readily available at
the present time.
Figure 8 Microscopic features of vWF, VEGF. BMP-2 and osteocalcin in subchondral bone in immunohistochemical stains.
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ESWT shows a number of treatment related chon-
droprotective effects and improves subchondral bone
remodeling in the initiation of osteoarthritis of the knee
in rats. Additional studies are needed to validate the
optimal ESWT dosage and the number of treatment for
osteoarthritis of the knee.
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